Pharmsville Co., Ltd. Share Price

Equities

A318010

KR7318010006

Food Processing

End-of-day quote Korea S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
6,610 KRW +0.15% Intraday chart for Pharmsville Co., Ltd. -1.78% -23.58%

Financials

Sales 2022 26.11B 18.98M 1.52B Sales 2023 21.39B 15.55M 1.25B Capitalization 67.32B 48.94M 3.92B
Net income 2022 4.06B 2.95M 237M Net income 2023 3.31B 2.41M 193M EV / Sales 2022 1.91 x
Net cash position 2022 35.55B 25.84M 2.07B Net cash position 2023 37.36B 27.16M 2.17B EV / Sales 2023 1.4 x
P/E ratio 2022
21.1 x
P/E ratio 2023
20.4 x
Employees 33
Yield 2022
0.92%
Yield 2023
-
Free-Float 28.16%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Pharmsville Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Tranche Update on Pharmsville Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Pharmsville Co., Ltd.'s Equity Buyback announced on September 15, 2023, has expired with 118,212 shares, representing 1.51% for KRW 998.83 million. CI
Tranche Update on Pharmsville Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Pharmsville Co., Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares. CI
Pharmsville Co., Ltd. authorizes a Buyback Plan. CI
Pharmsville Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Pharmsville Co., Ltd.'s Equity Buyback Plan announced on March 26, 2020. CI
Pharmsville Co., Ltd.'s Equity Buyback announced on March 26, 2020, has expired with 82,908 shares, representing 1.09% for KRW 998.09 million. CI
Tranche Update on Pharmsville Co., Ltd.'s Equity Buyback Plan announced on March 26, 2020. CI
Pharmsville Co., Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares. CI
Pharmsville Co., Ltd. authorizes a Buyback Plan. CI
FLY GANGWON Co., Ltd. announced that it has received KRW 3 billion in funding from Pharmsville Co.,Ltd. CI
FLY GANGWON Co., Ltd. announced that it expects to receive KRW 3 billion in funding from Pharmsville Co.,Ltd. CI
Pharmsville Co., Ltd. has completed an IPO in the amount of KRW 25.3575 billion. CI
More news
1 day+0.15%
1 week-1.78%
Current month-6.90%
1 month-3.50%
3 months-16.22%
6 months-22.24%
Current year-23.58%
More quotes
1 week
6 420.00
Extreme 6420
6 790.00
1 month
6 420.00
Extreme 6420
7 160.00
Current year
6 420.00
Extreme 6420
8 690.00
1 year
6 420.00
Extreme 6420
10 380.00
3 years
6 420.00
Extreme 6420
19 850.00
5 years
6 420.00
Extreme 6420
19 850.00
10 years
6 420.00
Extreme 6420
19 850.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 29/02/00
Chief Tech/Sci/R&D Officer 51 31/07/00
Comptroller/Controller/Auditor 59 -
Members of the board TitleAgeSince
Chief Executive Officer 61 29/02/00
Chief Tech/Sci/R&D Officer 51 31/07/00
Director/Board Member 70 -
More insiders
Date Price Change Volume
26/04/24 6,610 +0.15% 2,662
25/04/24 6,600 -0.30% 7,444
24/04/24 6,620 -1.05% 16,438
23/04/24 6,690 +0.60% 5,241
22/04/24 6,650 -1.19% 8,249

End-of-day quote Korea S.E., April 25, 2024

More quotes
Pharmsville Co., Ltd. is a Korea-based company principally engaged in the manufacturing and distribution of diet and health food. The Company manufactures and sells diet products under the brand name of Devil Diet. In addition, the Company manufactures and sells joint health, skin health supplement, eye health, nutritional supplement, immunity and antioxidation supplement food and other health functional food under the brand name of Apple Tree Dr. Kim, Vitamin Story, Apple Tree, Golden Garden, Apple Kinder, Daily Green and others. Moreover, the Company also manufactures and sells cosmetics and quasi drugs under the brand name of Doctor’s Answer.
More about the company
  1. Stock Market
  2. Equities
  3. A318010 Stock